S

St. Joseph's Health Care London | Ivey Eye Institute

Research site
(Unclaimed)
Location
268 Grosvenor Street Room B1-108, London, Ontario, Canada
Site insights

Top conditions

Macular Degeneration (8 trials)

Macular Edema (4 trials)

Edema (4 trials)

Open-Angle Glaucoma (3 trials)

Ocular Hypertension (3 trials)

Top treatments

Ranibizumab
VX-121
LX211
APL-2
Faricimab
Eylea
Pegcetacoplan
GSK3326595
Simufilam
Bimatoprost

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

6 of 43
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Enrolling
Uveitic Macular Edema
Drug: Vamikibart
Other: Sham

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Avacincaptad pegol 2 mg intravitreal injection

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

Trial sponsors

L

Lawson Health Research Institute (14 trials)

Roche logo

Roche (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems